Advertisement
Home »

Impact of IDO activation and alterations in the kynurenine pathway on hyperserotonemia, NAD production, and AhR activation in autism spectrum disorder.

Dec 11, 2023

ABOUT THE CONTRIBUTORS

  • Jean-Marie Launay

    Université Paris Cité and Inserm UMR-S 942 MASCOT, Paris, France. jean-marie.launay@inserm.fr.

    Richard Delorme

    Université Paris Cité and Child and Adolescent Psychiatry, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

    Cécile Pagan

    Service de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, 69500, Bron, France.

    Jacques Callebert

    Université Paris Cité and Inserm UMR-S 942 MASCOT, Paris, France.

    Department of Biochemistry, Hôpital Lariboisière – Fernand Widal, Assistance Publique-Hôpitaux de Paris, Paris, France.

    Marion Leboyer

    Université Paris Est Créteil and Inserm U955, IMRB, Translational Neuropsychiatry, Créteil, France.

    AP-HP, DMU IMPACT, FHU ADAPT, Hôpitaux Universitaires Henri Mondor, Créteil, France.

    Fondation FondaMental, Créteil, France.

    Nicolas Vodovar

    Université Paris Cité and Inserm UMR-S 942 MASCOT, Paris, France. nicolas.vodovar@inserm.fr.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement